Metabolic health WHO Europe report: key findings & action plan

Q: What does the WHO Europe report say about obesity in Europe?

WHO Europe reports that overweight and obesity have reached epidemic proportions across the Region and no Member State is currently on track to halt the rise; this underpins the call for scaled prevention and early detection. ([who.int](https://www.who.int/europe/news/item/03-05-2022-new-who-report--europe-can-reverse-its-obesity--epidemic?utm_source=openai))

Q: Which glucose values (mmol/L) indicate diabetes or prediabetes?

Fasting plasma glucose ≥7.0 mmol/L is diagnostic of diabetes; WHO IFG is 6.1–6.9 mmol/L while ADA uses 5.6–6.9 mmol/L for prediabetes; a 2‑hour OGTT ≥11.1 mmol/L is diagnostic. Confirm with a clinician. ([iris.who.int](https://iris.who.int/bitstream/handle/10665/325182/9789241515702-eng.pdf?utm_source=openai))

Q: Do Mediterranean or Nordic diets work for metabolic health?

Both dietary patterns have systematic review and trial evidence showing improvements in cardiometabolic markers; selection should be culturally adapted for adherence. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795232/?utm_source=openai))

Q: Can intermittent fasting lower fasting glucose?

Randomized trials and meta‑analyses indicate that time‑restricted eating can reduce fasting glucose and insulin for many adults, especially when combined with overall energy balance and early eating windows. ([bmjmedicine.bmj.com](https://bmjmedicine.bmj.com/content/5/1/e001071?utm_source=openai))

Q: What is the role of EFSA in food claims relevant to metabolic health?

EFSA issues scientific opinions on health claims (for example, certain beta‑glucan doses and reduced post‑prandial glycaemic responses). These opinions shape what products may lawfully claim in the EU single market. ([efsa.onlinelibrary.wiley.com](https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2011.2207?utm_source=openai))

الصحة الأيضية: تقرير منظمة الصحة العالمية إقليم أوروبا – النتائج الرئيسية

Author: Feras Alayed - Therapeutic & Behavioral Nutrition Specialist

Published: July 29, 2026

Category: european-health

Reading Time: 12 minutes

Key Takeaways

Overweight and obesity affect over half of adults in the EU (self-reported 2022 data) — a major driver of poor metabolic health. ([oecd.org](https://www.oecd.org/content/dam/oecd/en/publications/reports/2024/11/health-at-a-glance-europe-2024_bb301b77/b3704e14-en.pdf?utm_source=openai))
WHO Regional data show that no Member State is on track to halt the rise in obesity; metabolic complications (T2D, fatty liver, cardiometabolic disease) are rising across the Region. ([who.int](https://www.who.int/europe/news/item/03-05-2022-new-who-report--europe-can-reverse-its-obesity--epidemic?utm_source=openai))
Mediterranean and Nordic dietary patterns each have randomized- and cohort-level evidence for favourable metabolic outcomes; dietary quality matters more than a single nutrient. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795232/?utm_source=openai))
Time‑restricted eating (TRE)/intermittent fasting and structured lifestyle programmes can reduce fasting glucose, fasting insulin and waist circumference in controlled trials — benefits are often related to energy balance and timing. ([bmjmedicine.bmj.com](https://bmjmedicine.bmj.com/content/5/1/e001071?utm_source=openai))
EU-wide policy moves — cardiometabolic health checks and strengthened NCD prevention — are emerging, creating delivery opportunities across Member States. Individuals can complement system-level steps with evidence-aligned lifestyle changes and supportive systems (e.g., Feel Great). ([escardio.org](https://www.escardio.org/news/news-room/eu-cardiometabolic-health-checks-prioritising-prevention-and-early-detection-for-all/?utm_source=openai))

TL;DR

The WHO Regional Office for Europe finds escalating metabolic risk across the Region: high rates of overweight/obesity, growing diabetes burden and rising fatty‑liver signals demand policy and personal action. This article summarizes the report, links to Eurostat and EFSA evidence, highlights Mediterranean and Nordic dietary research, reviews intermittent‑fasting trial data, and outlines practical, non‑therapeutic ways to support metabolic health in Europe. ([who.int](https://www.who.int/europe/news/item/03-05-2022-new-who-report--europe-can-reverse-its-obesity--epidemic?utm_source=openai))

🇪🇺 Want to take action now? Try Feel Great → | Chat with a coach →

Metabolic Health in Europe: What the WHO Regional Report Means for People and Systems

Introduction — a shocking Europe statistic

More than half of people in the European Union reported being overweight or living with obesity in recent population surveys (2022 self‑report figures used in Health at a Glance: Europe). That is a population‑scale signal that metabolic risk (insulin resistance, type 2 diabetes, non‑alcoholic steatotic liver disease and cardiovascular risk clustering) is rising across EU health systems. ([oecd.org](https://www.oecd.org/content/dam/oecd/en/publications/reports/2024/11/health-at-a-glance-europe-2024_bb301b77/b3704e14-en.pdf?utm_source=openai))

Why the WHO regional perspective matters

The WHO Regional Office for Europe (WHO/Europe) compiles data across 53 Member States and issues regional analyses and action guidance that shape national priorities, surveillance systems and public‑health interventions. Its 2022 European Regional Obesity Report and ongoing NCD monitoring show that the Region is not on track to halt rising obesity and related metabolic disease — a finding echoed by EU statistics and by disease registries. The regional lens matters because many solutions require coordinated policy (food environments, fiscal measures, school and workplace programmes) and consistent primary‑care approaches across universal healthcare systems. ([who.int](https://www.who.int/europe/news/item/03-05-2022-new-who-report--europe-can-reverse-its-obesity--epidemic?utm_source=openai))

Key pieces of Europe evidence

1) Population burden — Eurostat & OECD/Health at a Glance

Self‑reported data used in 2022 show overweight/obesity is prevalent across EU Member States; the OECD 'Health at a Glance: Europe 2024' estimated hundreds of thousands of deaths in the EU attributable to high BMI and emphasised the economic pressure on universal healthcare systems. These figures are core to the WHO regional narrative that prevention must scale. ([oecd.org](https://www.oecd.org/content/dam/oecd/en/publications/reports/2024/11/health-at-a-glance-europe-2024_bb301b77/b3704e14-en.pdf?utm_source=openai))

2) Diabetes & cardiometabolic disease — IDF and regional datasets

The International Diabetes Federation (IDF) shows continued growth in diabetes prevalence in Europe and the Eurasian area, with substantial health system costs and human burden; WHO regional surveillance adds cause‑specific mortality and service‑coverage data that highlight gaps in early detection and integrated care. ([international-diabetes-federation.s3.eu-west-1.amazonaws.com](https://international-diabetes-federation.s3.eu-west-1.amazonaws.com/media/uploads/sites/3/2025/04/IDF_Atlas_11th_Edition_2025_Global-Factsheet.pdf?utm_source=openai))

3) Food, dietary patterns and regulatory evidence — EFSA and scientific reviews

EFSA scientific opinions and authorisations provide Europe‑specific evidence about food components that can modify post‑prandial glucose and lipid responses, notably beta‑glucans from oats and barley where EFSA concluded there is a substantiated relation to reduction of post‑prandial glycaemic responses under defined conditions. This matters for product labelling, formulation and consumer guidance across the EU single market. ([efsa.onlinelibrary.wiley.com](https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2011.2207?utm_source=openai))

What the clinical and trial evidence says (international context)

Large systematic reviews and randomized controlled trials (RCTs) in the last 5 years have tested dietary patterns, meal timing, and structured lifestyle programmes. Notable findings: (1) Mediterranean and similar high‑quality dietary patterns are associated with reduced cardiometabolic events and improved intermediate markers; (2) time‑restricted eating (TRE) and intermittent fasting protocols can decrease body weight, fasting glucose and fasting insulin in RCTs and meta‑analyses, with early‑window TRE sometimes showing stronger insulin benefits; (3) the primary mediator of many benefits is energy balance (weight loss), but timing and food quality provide additive effects. These findings are summarized in high‑quality reviews and RCTs (J Clin Endocrinol Metab, BMJ Medicine, NEJM among others). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795232/?utm_source=openai))

Europe‑specific diet evidence: Mediterranean and Nordic patterns

Research across Southern and Northern Europe shows two consistent themes: dietary quality (high vegetables, whole grains, legumes, fish, healthy oils) reduces cardiometabolic markers; and culturally adapted, regionally delivered food‑based guidelines perform better than one‑size‑fits‑all messages. Systematic reviews and umbrella reviews show Mediterranean patterns lower cardiovascular risk and improve markers linked to metabolic health; similarly, the Nordic diet (berries, root vegetables, oily fish, whole grain rye/bread) shows protective associations in large cohort analyses and randomized interventions in Sweden, Denmark and Finland. For policy and clinical guidance in EU health systems, both patterns are evidence‑based options that can be adapted to local food environments. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795232/?utm_source=openai))

Nordic research highlights

Malmö cohorts and Karolinska‑affiliated analyses link adipocyte characteristics and insulin resistance to later impaired glucose metabolism — showing how early metabolic change predicts clinical disease. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC13254842/?utm_source=openai))
Trials in Scandinavian settings testing Nordic‑style diets found improvements in blood lipids, waist circumference and markers of inflammation. These studies support Europe‑wide guidance on food patterns and public procurement. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5854836/?utm_source=openai))

Practical clinical thresholds (important to know — values in mmol/L)

Measure	Normal	Impaired / Pre‑diabetes	Diabetes threshold
Fasting plasma glucose (FPG)	<5.6 mmol/L	WHO IFG: 6.1–6.9 mmol/L; ADA prediabetes: 5.6–6.9 mmol/L	≥7.0 mmol/L (diagnostic)
2‑hour OGTT plasma glucose	<7.8 mmol/L	7.8–11.0 mmol/L (impaired glucose tolerance)	≥11.1 mmol/L (diagnostic)
Random plasma glucose (with symptoms)	—	—	≥11.1 mmol/L (diagnostic)

Sources: WHO and ADA diagnostic criteria and reviews. Note that Europe clinicians most commonly use WHO/IDF/ADA thresholds for screening and confirmation. Always confirm individual results with a healthcare professional. ([iris.who.int](https://iris.who.int/bitstream/handle/10665/325182/9789241515702-eng.pdf?utm_source=openai))

Health system & policy responses in Europe

WHO/Europe and European clinical societies have emphasised integrated approaches: prevention (food environments, SSB taxes, marketing restrictions), early detection (structured cardiometabolic health checks being discussed for EU roll‑out), and primary‑care capacity to deliver lifestyle interventions. Recent Task Force recommendations call for standardised cardiometabolic check programmes adaptable across EU Member States to fit universal coverage systems and local priorities. These are essential because many countries still lack consistent early‑detection pathways. ([who.int](https://www.who.int/europe/news/item/03-05-2022-new-who-report--europe-can-reverse-its-obesity--epidemic?utm_source=openai))

What the evidence means for an individual in Europe — practical steps

Get baseline measures: fasting glucose, lipids, blood pressure, waist circumference and BMI through primary care (supported by universal health coverage in most EU systems). Early detection matters because interventions are most effective before irreversible organ damage. ([gateway.euro.who.int](https://gateway.euro.who.int/en/indicators/hfamdb_334-sdr-endocrine-nutritional-and-metabolic-diseases-per-100-000/?utm_source=openai))
Improve dietary quality first: adopt a Mediterranean or Nordic‑inspired pattern that emphasises vegetables, legumes, whole grains (including oat/barley beta‑glucans where appropriate), oily fish and healthy oils. EFSA opinions provide European context for certain food claims (e.g., beta‑glucans and post‑prandial glycaemia). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795232/?utm_source=openai))
Consider meal timing: evidence from RCTs and meta‑analyses shows time‑restricted eating can reduce fasting glucose and insulin and promote modest weight loss — especially when paired with energy balance and earlier eating windows. Use TRE approaches that fit personal schedules and medical context. ([bmjmedicine.bmj.com](https://bmjmedicine.bmj.com/content/5/1/e001071?utm_source=openai))
Stay active and reduce sedentary time: exercise improves insulin sensitivity independent of weight change. Combine dietary changes with regular moderate activity. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12899630/?utm_source=openai))
Use regulated, evidence‑based products and services for support (not as replacements for medical care). If using functional food products or supplements, look for EFSA‑evaluated claims or high‑quality clinical evidence, and check national regulation and delivery options across EU Member States. ([efsa.onlinelibrary.wiley.com](https://efsa.onlinelibrary.wiley.com/doi/abs/10.2903/j.efsa.2021.6493?utm_source=openai))

How Feel Great Helps (connecting the system to metabolic health)

As a lifestyle support system (not a medication), Feel Great is positioned to work alongside public health and primary care steps. Elements of Feel Great that align with European evidence include:

Balance — a soluble fiber matrix (including ingredients comparable to oat/barley beta‑glucans) that may help moderate post‑meal glucose peaks when consumed under the conditions described in EFSA evaluations. This may help manage post‑prandial glycaemic responses as part of an overall dietary pattern. Note: EFSA has issued opinions on beta‑glucans and post‑prandial glycaemia under defined conditions; product use should follow those conditions. ([efsa.onlinelibrary.wiley.com](https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2011.2207?utm_source=openai))
Unimate (yerba mate extract) — contains chlorogenic acids and other polyphenols that, in trials of similar compounds, have been associated with modest effects on energy and mental clarity; such botanical extracts are best used as part of a comprehensive lifestyle plan and in line with EFSA and national regulations. (Not a medication — may support energy and focus in day‑to‑day life.) ([mdpi.com](https://www.mdpi.com/2076-3417/10/7/2387?utm_source=openai))
4‑4‑12 intermittent fasting protocol — a structured timing strategy (as one form of time‑restricted eating). RCTs and meta‑analyses of TRE show timing can influence fasting glucose and insulin, particularly when eating windows are earlier in the day and combined with energy balance. Individuals should use such protocols under professional advice if they have medical conditions (e.g., diabetes). ([bmjmedicine.bmj.com](https://bmjmedicine.bmj.com/content/5/1/e001071?utm_source=openai))
Clinical evidence & delivery — Feel Great references 50+ clinical studies in its PDR‑listed materials; any product or programme intended for EU consumers should be delivered respecting EU regulations, EFSA claims and national healthcare systems (delivery across Member States is feasible but must follow local rules). Feel Great is framed as a lifestyle support that may help people manage post‑meal responses, energy and daily routines — not as a therapy. ([efsa.onlinelibrary.wiley.com](https://efsa.onlinelibrary.wiley.com/doi/abs/10.2903/j.efsa.2026.9942?utm_source=openai))

Comparison table — interventions and expected effects (evidence level)

Intervention	Typical effects on metabolic markers	Evidence level (2021–2026)
Mediterranean diet	Lower BP, improved lipids, modest HbA1c and weight effects	Systematic reviews & RCTs (high‑moderate). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795232/?utm_source=openai))
Nordic diet	Improved lipids, waist circumference, inflammation markers	Prospective cohorts & RCTs (moderate). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9630197/?utm_source=openai))
Time‑restricted eating (TRE)	Reduced fasting glucose & insulin, weight loss (often small‑moderate)	RCTs & meta‑analyses (moderate). Effects linked to energy intake and timing. ([bmjmedicine.bmj.com](https://bmjmedicine.bmj.com/content/5/1/e001071?utm_source=openai))
Soluble fiber / beta‑glucans	Reduced post‑prandial glucose peaks under defined doses	EFSA‑evaluated human intervention studies (Europe‑specific). ([efsa.onlinelibrary.wiley.com](https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2011.2207?utm_source=openai))

Frequently Asked Questions (FAQ)

What is "metabolic health"? — It refers to how well the body regulates blood glucose, lipids, blood pressure and body composition. Poor metabolic health often shows as insulin resistance, dyslipidaemia, high blood pressure or increased waist circumference. ([nature.com](https://www.nature.com/articles/s41572-024-00563-5?utm_source=openai))
Should I start time‑restricted eating? — TRE can be helpful for some people but is not required. Talk to a clinician if you have diabetes, take glucose‑lowering medication, are pregnant, or have other medical conditions. ([bmjmedicine.bmj.com](https://bmjmedicine.bmj.com/content/5/1/e001071?utm_source=openai))
Do functional foods work? — Some ingredients (e.g., oat/barley beta‑glucans) have EFSA‑substantied effects on post‑meal glycaemia in defined doses; they can be integrated into dietary patterns but are not a substitute for broader diet quality. ([efsa.onlinelibrary.wiley.com](https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2011.2207?utm_source=openai))
How will EU health systems respond? — Policies emphasise prevention, standardised checks and integration across primary care. Delivery will vary by Member State but EU recommendations aim to support uniform standards. ([escardio.org](https://www.escardio.org/news/news-room/eu-cardiometabolic-health-checks-prioritising-prevention-and-early-detection-for-all/?utm_source=openai))
Where can I get reliable guidance? — Use WHO Europe, national public‑health bodies, professional societies (EASD, ESC), and primary care clinicians for personalised advice. For product choices, look for EFSA opinions and national authorisations. ([who.int](https://www.who.int/europe/news/item/03-05-2022-new-who-report--europe-can-reverse-its-obesity--epidemic?utm_source=openai))

Action checklist for clinicians and health leaders (EU focus)

Implement standard cardiometabolic checks and referral pathways in primary care, aligned with Task Force recommendations. ([escardio.org](https://www.escardio.org/news/news-room/eu-cardiometabolic-health-checks-prioritising-prevention-and-early-detection-for-all/?utm_source=openai))
Use evidence‑based dietary guidance (Mediterranean/Nordic patterns) and consider EFSA‑evaluated functional foods as adjuncts. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795232/?utm_source=openai))
Promote TRE and activity protocols in lifestyle programmes where appropriate, and measure fasting glucose in mmol/L to track changes. ([bmjmedicine.bmj.com](https://bmjmedicine.bmj.com/content/5/1/e001071?utm_source=openai))
Strengthen surveillance using Eurostat/OECD indicators and link with WHO regional databases to monitor progress. ([oecd.org](https://www.oecd.org/content/dam/oecd/en/publications/reports/2024/11/health-at-a-glance-europe-2024_bb301b77/b3704e14-en.pdf?utm_source=openai))

References & Scientific Sources

WHO Regional Office for Europe — European Regional Obesity Report (WHO Europe). ([who.int](https://www.who.int/europe/news/item/03-05-2022-new-who-report--europe-can-reverse-its-obesity--epidemic?utm_source=openai))
Eurostat / Health at a Glance: Europe (OECD & EU) — overweight & obesity indicators (2022–2024). ([oecd.org](https://www.oecd.org/content/dam/oecd/en/publications/reports/2024/11/health-at-a-glance-europe-2024_bb301b77/b3704e14-en.pdf?utm_source=openai))
EFSA Scientific Opinions on beta‑glucans and reduction of post‑prandial glycaemic responses (2011; 2021; opinions/2025–2026 modifications). ([efsa.onlinelibrary.wiley.com](https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2011.2207?utm_source=openai))
IDF Diabetes Atlas / IDF Europe regional materials (2024–2025). ([international-diabetes-federation.s3.eu-west-1.amazonaws.com](https://international-diabetes-federation.s3.eu-west-1.amazonaws.com/media/uploads/sites/3/2025/04/IDF_Atlas_11th_Edition_2025_Global-Factsheet.pdf?utm_source=openai))
BMJ Medicine network meta‑analysis on timing & TRE (2024). ([bmjmedicine.bmj.com](https://bmjmedicine.bmj.com/content/5/1/e001071?utm_source=openai))
J Clin Endocrinol Metab systematic review & meta‑analysis on TRE (2022/2023). ([academic.oup.com](https://academic.oup.com/jcem/article/107/12/3428/6747530?utm_source=openai))
NEJM trial — Calorie restriction with or without TRE (2018–2021 trial; NEJM). ([nejm.org](https://www.nejm.org/doi/full/10.1056/NEJMoa2114833?utm_source=openai))
Nordic diet systematic review & meta‑analysis (2022–2023). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9630197/?utm_source=openai))
Karolinska / Malmö cohort studies on adipocyte volume and later impaired glucose metabolism. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC13254842/?utm_source=openai))
Lancet Regional Health – Europe commentary on metabolic policy & MASLD (2026). ([doi.org](https://doi.org/10.1016/j.lanepe.2026.101713?utm_source=openai))

Medical disclaimer

This article is educational and not a substitute for medical advice. It summarizes WHO regional findings and scientific literature but does not provide individualized diagnosis or treatment. Always consult a qualified healthcare professional before making major changes to diet, exercise, fasting protocols or starting supplements, particularly if you have diabetes, are pregnant, are taking prescription medicines, or have other chronic conditions.

🇪🇺 Ready to Start Your Health Transformation?

Join thousands across Europe who have improved their metabolic health with the Feel Great system. Backed by 50+ clinical studies and listed in the Physicians' Desk Reference (PDR).

🛒 Order Feel Great — Free Delivery Across EU Member States 💬 Chat with a Health Coach 📋 Take Free Health Assessment ⭐ View Success Stories

✅ Free Delivery Across EU Member States | 90-Day Money-Back Guarantee

أهم النقاط

أكثر من نصف البالغين في الاتحاد الأوروبي أفادوا بزيادة الوزن أو السمنة في بيانات الاستبيانات الذاتية لعام 2022 — عامل رئيسي يؤثر على الصحة الأيضية. ([oecd.org](https://www.oecd.org/content/dam/oecd/en/publications/reports/2024/11/health-at-a-glance-europe-2024_bb301b77/b3704e14-en.pdf?utm_source=openai))
تُظهر بيانات منظمة الصحة العالمية الإقليمية أن الدول الأعضاء لم تكن في مسار تحقيق هدف وقف ارتفاع السمنة، مع تزايد مضاعفات التمثيل الغذائي (السكري من النمط الثاني، مرض الكبد الدهني الأيضي، وأمراض القلب والأوعية الدموية). ([who.int](https://www.who.int/europe/news/item/03-05-2022-new-who-report--europe-can-reverse-its-obesity--epidemic?utm_source=openai))
الأدلة من بحوث حمية البحر المتوسط والدراسات الإسكندنافية تدعم تحسّن المؤشرات الأيضية عند اتباع أنماط غذائية عالية الجودة. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795232/?utm_source=openai))
الصيام المتقطع/تقييد وقت الأكل قد يخفض الجلوكوز الصائم والإنسولين الصائم في تجارب عشوائية، لكن الأثر غالباً يرتبط بمستوى الطاقة/التوازن الحراري. ([bmjmedicine.bmj.com](https://bmjmedicine.bmj.com/content/5/1/e001071?utm_source=openai))
توصيات على مستوى الاتحاد الأوروبي لتنفيذ فحوصات صحية قلبية‑أيضية موحدة تفتح فرصاً لتقديم التدخلات المبكرة عبر نظم الرعاية الصحية الشاملة في الدول الأعضاء. ([escardio.org](https://www.escardio.org/news/news-room/eu-cardiometabolic-health-checks-prioritising-prevention-and-early-detection-for-all/?utm_source=openai))

الخلاصة المختصرة

تُشير تقارير منظمة الصحة العالمية لإقليم أوروبا إلى ارتفاع مخاطر الأيض في المنطقة. يوضح هذا المقال نتائج التقرير، بيانات يوروستات، أدلة من دول الشمال والمتوسط، أحدث التجارب حول توقيت الأكل، واقتراحات عملية متوافقة مع اللوائح الأوروبية (بما في ذلك آراء EFSA على أطعمة محددة). ([who.int](https://www.who.int/europe/news/item/03-05-2022-new-who-report--europe-can-reverse-its-obesity--epidemic?utm_source=openai))

🇪🇺 هل تريد اتخاذ خطوة الآن؟ جرب Feel Great ← | تحدث مع مدرب ←

الصحة الأيضية في أوروبا: ماذا يعني تقرير منظمة الصحة العالمية الإقليمي؟

مقدمة — إحصائية مُلفتة

أفاد أكثر من نصف سكان الاتحاد الأوروبي عن زيادة في الوزن أو السمنة في بيانات عام 2022، وهو مؤشر واضح على ارتفاع عوامل الخطر الأيضية التي تشمل مقاومة الإنسولين والسكري ومرض الكبد الدهني. تؤكد منظمة الصحة العالمية الإقليمية وأجهزة الإحصاء الأوروبية أن الوقاية والفحص المبكر يجب أن يتوسعا. ([oecd.org](https://www.oecd.org/content/dam/oecd/en/publications/reports/2024/11/health-at-a-glance-europe-2024_bb301b77/b3704e14-en.pdf?utm_source=openai))

لماذا يعتبر منظور منظمة الصحة العالمية الإقليمي مهماً؟

توحد منظمة الصحة العالمية بيانات 53 دولة إقليمية وتقدم رؤى واستراتيجيات يمكن أن توجه السياسات الوطنية — من تنظيم بيئات الطعام إلى برامج الفحص والتدخل في الرعاية الأولية، وهي جوانب أساسية لأن غالبية دول أوروبا لديها نظم رعاية صحية شاملة تغطي الفحوصات الأساسية. ([who.int](https://www.who.int/europe/news/item/03-05-2022-new-who-report--europe-can-reverse-its-obesity--epidemic?utm_source=openai))

الأدلة الأساسية المرتبطة بأوروبا

العبء السكاني — بيانات يوروستات وHealth at a Glance

تعكس تقارير Eurostat وOECD أن نسب زيادة الوزن والسمنة مرتفعة عبر دول الاتحاد الأوروبي، مع تأثير واضح على الوفيات والضغط على أنظمة الرعاية الصحية العامة. ([oecd.org](https://www.oecd.org/content/dam/oecd/en/publications/reports/2024/11/health-at-a-glance-europe-2024_bb301b77/b3704e14-en.pdf?utm_source=openai))

السكري والوقاية — ما تقوله بيانات IDF ومنظمات المنطقة

يستمر عبء مرض السكري في الزيادة، وتوضح تقارير IDF ونُظم المراقبة الإقليمية وجود فجوات في الكشف المبكر والتكامل العلاجي. ([international-diabetes-federation.s3.eu-west-1.amazonaws.com](https://international-diabetes-federation.s3.eu-west-1.amazonaws.com/media/uploads/sites/3/2025/04/IDF_Atlas_11th_Edition_2025_Global-Factsheet.pdf?utm_source=openai))

الأطعمة والادعاءات التنظيمية — دور EFSA

أصدرت EFSA آراء علمية عن مكونات غذائية محددة (مثل بيتا‑جلوكانات الشعير والشوفان) وتقليل ارتفاعات السكر بعد الوجبات ضمن جرعات وشروط محددة — وهو أمر ذي صلة عندما يختار المستهلكون منتجات مُعلنة في سوق الاتحاد الأوروبي. ([efsa.onlinelibrary.wiley.com](https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2011.2207?utm_source=openai))

ماذا تقول التجارب والأدلة العالمية؟

الملخص العلمي: الحميات عالية الجودة (متوسطي/شمالي) تُحسّن علامات الخطر؛ تقييد وقت الأكل يخفض جلوكوز الصيام والإنسولين في العديد من التجارب؛ والنتائج العملية تعتمد على الالتزام، توقيت الوجبات، والجملة الغذائية الشاملة أكثر من عنصر واحد. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795232/?utm_source=openai))

القيم السريرية المهمة (بـ mmol/L)

القياس	المعدل الطبيعي	مرحلة معرّضة / قبل السكري	عتبة السكري
جلوكوز صائم (FPG)	<5.6 mmol/L	WHO IFG: 6.1–6.9 mmol/L؛ ADA: 5.6–6.9 mmol/L	≥7.0 mmol/L (تشخيصي)
OGTT بعد ساعتين	<7.8 mmol/L	7.8–11.0 mmol/L (اختلال تحمل الجلوكوز)	≥11.1 mmol/L (تشخيصي)

المصادر: إرشادات WHO وADA. تأكد من تفسير النتائج مع مقدم الرعاية. ([iris.who.int](https://iris.who.int/bitstream/handle/10665/325182/9789241515702-eng.pdf?utm_source=openai))

كيف يمكن للأفراد أن يتصرفوا؟

اطلب فحوصات أساسية في الرعاية الأولية (صائم، شحوم، ضغط، محيط خصر). ([gateway.euro.who.int](https://gateway.euro.who.int/en/indicators/hfamdb_334-sdr-endocrine-nutritional-and-metabolic-diseases-per-100-000/?utm_source=openai))
حسّن نوعية الغذاء — حمية البحر المتوسط أو النرويجية قد تكون خطوات عملية قابلة للتكيّف. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11795232/?utm_source=openai))
فكّر في تقييد وقت الأكل إن كان مناسبا لك؛ راجع الطبيب إذا كنت تتناول أدوية خافضة للسكر. ([bmjmedicine.bmj.com](https://bmjmedicine.bmj.com/content/5/1/e001071?utm_source=openai))
استمرّ بالنشاط البدني وقلل الجلوس. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12899630/?utm_source=openai))

دور برنامج "Feel Great" (توضيح الارتباط)

يُقدم نظام Feel Great عناصر داعمة للحياة اليومية (مصفوفة ألياف قابلة للذوبان مثل Balance، مستخلص اليربا ماتي Unimate، وبروتوكول توقيت الأكل 4‑4‑12) التي قد تساعد الأشخاص على تنظيم استجابات ما بعد الوجبة وطاقة اليوم. هذه الأدوات لا تُعد أدوية، ويجب استخدامها كجزء من نمط حياة شامل، وفق الأدلّ ة الأوروبية وضمن الحدود المصرح بها من EFSA والهيئات الوطنية. ([efsa.onlinelibrary.wiley.com](https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2011.2207?utm_source=openai))

الأسئلة الشائعة

ما الفرق بين السمنة والخلل الأيضي؟ — السمنة تشير إلى تراكم دهون مفرط؛ الخلل الأيضي يشمل مقاومة الإنسولين واضطرابات في الشحوم والضغط. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/?utm_source=openai))
هل يجب أن أبدأ صياما متقطعا؟ — قد يفيد بعض الأشخاص، لكن تحدث مع الطبيب خصوصا إذا لديك أدوية أو حالات طبية. ([bmjmedicine.bmj.com](https://bmjmedicine.bmj.com/content/5/1/e001071?utm_source=openai))
هل هناك أطعمة معتمدة رسمياً لفائدة خفض سكر ما بعد الوجبة؟ — EFSA قد أيدت أدلة بيتا‑غلوكان بجرعات وشروط محددة لخفض ارتفاع السكر بعد الوجبات. ([efsa.onlinelibrary.wiley.com](https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2011.2207?utm_source=openai))
كيف تؤثر سياسات الاتحاد الأوروبي؟ — توصيات فحوصات صحية قلبية‑أيضية موحدة قد تُحسن الاكتشاف المبكر وتناسق الرعاية بين الدول الأعضاء. ([escardio.org](https://www.escardio.org/news/news-room/eu-cardiometabolic-health-checks-prioritising-prevention-and-early-detection-for-all/?utm_source=openai))
من أين أجد معلومات موثوقة؟ — منظمة الصحة العالمية الإقليمية، يوروستات، EFSA، وجمعيات مهنية مثل EASD/ESC. ([who.int](https://www.who.int/europe/news/item/03-05-2022-new-who-report--europe-can-reverse-its-obesity--epidemic?utm_source=openai))

قائمة المراجع

منظمة الصحة العالمية – تقرير السمنة الإقليمي لأوروبا. ([who.int](https://www.who.int/europe/news/item/03-05-2022-new-who-report--europe-can-reverse-its-obesity--epidemic?utm_source=openai))
Eurostat وHealth at a Glance: Europe (OECD) بيانات السمنة والوزن الزائد. ([oecd.org](https://www.oecd.org/content/dam/oecd/en/publications/reports/2024/11/health-at-a-glance-europe-2024_bb301b77/b3704e14-en.pdf?utm_source=openai))
EFSA آراء علمية حول بيتا‑غلوكان وتقليل استجابة الجلوكوز بعد الوجبة. ([efsa.onlinelibrary.wiley.com](https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2011.2207?utm_source=openai))
IDF Europe وIDF Atlas إحصاءات السكري الإقليمية. ([international-diabetes-federation.s3.eu-west-1.amazonaws.com](https://international-diabetes-federation.s3.eu-west-1.amazonaws.com/media/uploads/sites/3/2025/04/IDF_Atlas_11th_Edition_2025_Global-Factsheet.pdf?utm_source=openai))
مراجعات منهجية وRCTs حول توقيت الأكل والصيام المتقطع (BMJ Medicine، J Clin Endocrinol Metab، NEJM). ([bmjmedicine.bmj.com](https://bmjmedicine.bmj.com/content/5/1/e001071?utm_source=openai))
دراسات وحلقات بحث إسكندنافية (Karolinska، Malmö) حول مقاومة الإنسولين وتوزيع الأنسجة الدهنية. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC13254842/?utm_source=openai))

تنويه طبي

هذا المحتوى معلوماتي وتعليمي فقط ولا يُعد بديلاً عن المشورة الطبية الشخصية. قبل تعديل نظامك الغذائي بشكل جذري أو البدء في بروتوكولات صيام أو استخدام مكملات، استشر طبيبك أو اختصاصي الرعاية الصحية، خاصةً إذا كنت مصاباً بالسكري أو تتناول أدوية وصفية.

🇪🇺 هل أنت مستعد لبدء تحولك الصحي؟

انضم لآلاف الأشخاص في أوروبا الذين حسّنوا صحتهم الأيضية مع نظام Feel Great. مدعوم بأكثر من 50 دراسة سريرية.

🛒 اطلب Feel Great الآن 💬 تحدث مع مدرب صحي 📋 تقييم صحي مجاني

Frequently Asked Questions

What does the WHO Europe report say about obesity in Europe?